APA (7th ed.) Citation

Marchetti, M., & Hehlmann, R. (2017). Which patients with myelofibrosis should receive ruxolitinib therapy?: ELN-SIE evidence-based recommendations. Leukemia, 31(4), . https://doi.org/10.1038/leu.2016.283

Chicago Style (17th ed.) Citation

Marchetti, Marco, and Rüdiger Hehlmann. "Which Patients with Myelofibrosis Should Receive Ruxolitinib Therapy?: ELN-SIE Evidence-based Recommendations." Leukemia 31, no. 4 (2017). https://doi.org/10.1038/leu.2016.283.

MLA (9th ed.) Citation

Marchetti, Marco, and Rüdiger Hehlmann. "Which Patients with Myelofibrosis Should Receive Ruxolitinib Therapy?: ELN-SIE Evidence-based Recommendations." Leukemia, vol. 31, no. 4, 2017, https://doi.org/10.1038/leu.2016.283.